Bevacizumab (Avastin<sup>&reg;</sup>) for the management of anterior chamber neovascularization and neovascular glaucoma

Dimitrios Brouzas; Antonios Charakidas; Marilita Moschos; Chryssanthi Koutsandrea; Michael Apostolopoulos; Stefanos Baltatzis

doi:10.2147/OPTH.S7698

open access to scientific and medical research

Back to Journals » Clinical Ophthalmology » Volume 3

Other

Bevacizumab (Avastin^®) for the management of anterior chamber neovascularization and neovascular glaucoma

Total article views		HTML views	PDF downloads	Totals
9,484	Dovepress*	9,484+	3,295	12,779
9,484	Totals	9,484	3,295	12,779
*Since 20 November 2009 +Since July 2016

View citations on Google Scholar

In order to provide our website visitors and registered users with a service tailored to their individual preferences we use cookies to analyse visitor traffic and personalise content. You can learn about our use of cookies by reading our Privacy Policy. We also retain data in relation to our visitors and registered users for internal purposes and for sharing information with our business partners. You can learn about what data of yours we retain, how it is processed, who it is shared with and your right to have your data deleted by reading our Privacy Policy.

If you agree to our use of cookies and the contents of our Privacy Policy please click 'accept'.

Bevacizumab (Avastin®) for the management of anterior chamber neovascularization and neovascular glaucoma

Bevacizumab (Avastin^®) for the management of anterior chamber neovascularization and neovascular glaucoma